Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02268253
Title Tagraxofusp (SL-401) in Patients With CMML or MF
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Stemline Therapeutics, Inc.
Indications

myelofibrosis

chronic myelomonocytic leukemia

Therapies

Tagraxofusp-erzs

Age Groups: adult | senior
Covered Countries USA | CAN

Additional content available in CKB BOOST